首站-论文投稿智能助手
典型文献
Surgical management in pediatric neuroblastoma diagnosis and treatment:a 20-year,single-center experience
文献摘要:
Background The currently utilized International Neuroblastoma Risk Group (INRG) staging system developed in 2009 uses image-defined risk factors as a measure of surgical risk,separating resectable neuroblastoma from those best preceded by chemotherapy.The previous International Neuroblastoma Staging System was based primarily on surgical findings.We hypothesized there would be a change to the role of the surgeon in neuroblastoma treatment in the more recent decade.Methods This is a single center 20-year retrospective analysis of 104 patients with International Classification of Diseases-9 and-10 codes for neuroblastoma.Patient demographics,tumor site,cancer treatment modality,survival,biopsy technique,surgical intervention,and pathology staging were collected.Data was analyzed by analysis of variance (ANOVA) and Stu-dent's t test.Results There was a decrease in open surgeries for extra-adrenal neuroblastomas in the later decade (77%,31%,P =0.01).There was a narrowing of the time interval to surgery in the later cohort,likely as a result of uniformity in surgical timing on treatment protocols relying on INRG staging.Conclusions Our findings mirror changes in practice patterns globally.We found an increase in minimally invasive approaches but did not find a difference in the role of the surgeon under the INRG staging system.
文献关键词:
作者姓名:
Brianna Spencer;Akshilkumar Patel;Robert Cilley;Christa N.Grant
作者机构:
Department of Surgery,Penn State Health Milton S.Hershey Medical Center,500 University Drive,Hershey,PA 17033,USA;Pennsylvania State University College of Medicine,Hershey,PA,USA;Division of Pediatric Surgery,Penn State Health Milton S.Hershey Medical Center,Hershey,PA,USA
引用格式:
[1]Brianna Spencer;Akshilkumar Patel;Robert Cilley;Christa N.Grant-.Surgical management in pediatric neuroblastoma diagnosis and treatment:a 20-year,single-center experience)[J].世界儿科杂志(英文版),2022(02):120-125
A类:
INRG,neuroblastomas
B类:
Surgical,management,pediatric,diagnosis,treatment,year,single,center,experience,Background,currently,utilized,International,Neuroblastoma,Risk,Group,staging,system,developed,uses,image,defined,risk,factors,measure,surgical,separating,resectable,from,those,best,preceded,by,chemotherapy,previous,Staging,System,was,primarily,findings,We,hypothesized,there,would,role,surgeon,more,recent,decade,Methods,This,retrospective,analysis,patients,Classification,Diseases,codes,Patient,demographics,tumor,site,cancer,modality,survival,biopsy,technique,intervention,pathology,were,collected,Data,analyzed,variance,ANOVA,Stu,dent,test,Results,There,decrease,open,surgeries,extra,adrenal,later,narrowing,interval,surgery,cohort,likely,result,uniformity,timing,protocols,relying,Conclusions,Our,mirror,changes,practice,patterns,globally,found,increase,minimally,invasive,approaches,but,did,not,difference,under
AB值:
0.627745
相似文献
Treatment patterns and a prognostic scoring system for elderly acute myeloid leukemia patients: a retrospective multicenter cohort study in China
Chunli Zhang;Wei Wan;Shuai Zhang;Jingwen Wang;Ru Feng;Jiangtao Li;Junyue Chai;Hebing Zhou;Liru Wang;Yuping Zhong;Xiaodong Mo;Mengzhu Shen;Hongmei Jing;Hui Liu-Department of Hematology,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing 100730,China;Department of Hematology,Peking University Third Hospital,Beijing 100191,China;Department of Hematology,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China;Department of Hematology,Beijing No.6 Hospital,Beijing 100007,China;Department of Hematology,Beijing Luhe Hospital,Capital Medical University,Beijing 101100,China;Department of Hematology,Fuxing Hospital,Capital Medical University,Beijing 100038,China;Department of Hematology,Beijing Chao-Yang Hospital,Capital Medical University,Beijing 100043,China;Peking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,China
Comparison of outcomes between immediate implant- based and autologous reconstruction: 15-year, single-center experience in a propensity score-matched Chinese cohort
Shanshan He;Bowen Ding;Gang Li;Yubei Huang;Chunyong Han;Jingyan Sun;Qingfeng Huang;Jing Liu;Zhuming Yin;Shu Wang;Jian Yin-Department of Breast Reconstruction,Key Laboratory of Breast Cancer Prevention and Therapy,Tianjin Medical University,Ministry of Education,Sino-Russian Joint Research Center for Oncoplastic Breast Surgery,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China;School of Pharmacy,University College London,London WC1N 1AX,UK;Department of Cancer Epidemiology and Biostatistics,Tianjin Medical University Cancer Institute&Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China
Risk of gestational diabetes recurrence and the development of type 2 diabetes among women with a history of gestational diabetes and risk factors: a study among 18 clinical centers in China
Wei Yumei;Juan Juan;Su Rina;Song Geng;Chen Xu;Shan Ruiqin;Li Ying;Cui Shihong;Fan Shangrong;Feng Ling;You Zishan;Meng Haixia;Cai Yan;Zhang Cuilin;Yang Huixia-Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing 100034, China;Department of Obstetrics, Tianjin Central Obstetrics and Gynecology Hospital, Tianjin 300199, China;Department of Obstetrics, Jinan Maternal and Child Health Hospital, Jinan, Shandong 250000, China;Department of Obstetrics, Dalian Maternity Hospital, Dalian, Liaoning 116033, China;Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China;Department of Obstetrics, Shenzhen Peking University Hospital, Shenzhen, Guangdong 518036, China;Department of Obstetrics and Gynecology, Tongji Hospital Affiliated to Huazhong University of Science and Technology, Wuhan, Hubei 430030, China;Department of Obstetrics and Gynecology, Suzhou Jiulong Hospital Affiliated to Shanghai Jiaotong University, Suzhou, Jiangsu 320571, China;Department of Obstetrics, Affiliated Hospital of Inner Mongolia Medical University, Huhhot, Inner Mongolia 010050, China;Department of Obstetrics and Gynecology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China;Epidemiology Branch, Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20817, USA
Sex differences in systemic lupus erythematosus (SLE): an inception cohort of the Chinese SLE Treatment and Research Group (CSTAR) registry XVII
Gui Yinli;Bai Wei;Xu Jian;Duan Xinwang;Zhan Feng;Zhao Chen;Jiang Zhenyu;Li Zhijun;Wu Lijun;Liu Shengyun;Yang Min;Wei Wei;Wang Ziqian;Zhao Jiuliang;Wang Qian;Leng Xiaomei;Tian Xinping;Li Mengtao;Zhao Yan;Zeng Xiaofeng;CSTAR co-authors-Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China;Department of Rheumatology, The People’s Hospital of Zhengzhou, Zhengzhou, Henan 450003, China;Department of Rheumatology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, China;Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China;Department of Rheumatology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570311, China;Department of Rheumatology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China;Department of Rheumatology, The Bethune First Hospital of Jilin University, Changchun, Jilin 130021, China;Department of Rheumatology, The Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China;Department of Rheumatology, The People’s Hospital of Xinjiang Autonomous Region, Urumqi, Xinjiang 830001, China;Department of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China;Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China;Department of Rheumatology, Tianjin Medical University General Hospital, Tianjin 300052, China
Exosomal miR-485-3p derived from pancreatic ductal epithelial cells inhibits pancreatic cancer metastasis through targeting PAK1
Li Mingzhe;Zhou Jiaxin;Zhang Zhengkui;Li Jisong;Wang Feng;Ma Ling;Tian Xiaodong;Mao Zebin;Yang Yinmo-Department of General Surgery, Peking University First Hospital, Beijing 100034, China;Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, Zhejiang 310016, China;Department of Gastrointestinal Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China;Department of Surgical Oncology, Peking University Ninth School of Clinical Medicine (Beijing Shijitan Hospital, Capital Medical University), Beijing 100038, China;Department of Medical Biochemistry and Molecular Biology, Peking University Health Science Center, Beijing 100191, China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。